Goldman says this biotech stock will be a winner thanks to a one-of-a-king treatment
Hemab Therapeutics will likely see more upside in the wake of its recent public listing due to its progress toward developing the first treatment for a pair of rare bleeding disorders, according to Goldman Sachs. The investment bank, which was one of the company’s IPO underwriters, initiated coverage of the biotechnology name with a buy …